AGP Picks
View all

AGP Executive Report

Your go-to archive of top headlines, summarized for quick and easy reading.

Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.

Cancer Care: The European Commission approved RASONQUE (daraxonrasib), a once-daily oral treatment for adults with metastatic pancreatic cancer after at least one prior systemic therapy. Patient access will depend on national pricing and reimbursement. Lung Cancer: EMA advisers recommended Zybrivo (sintilimab) with chemotherapy as a first-line option for advanced non-squamous lung cancer; European Commission approval is still pending. Rare Conditions: The EU approved Zeydovio (glepaglutide), a twice-weekly treatment for adults with short bowel syndrome, marking the first major European treatment advance for the condition in more than a decade. Regional Health Preparedness: ECDC is preparing to roll out Epi+, a multilingual platform to help nine countries detect and coordinate responses to emerging public-health threats next year. Liechtenstein-Relevant Decisions: EU advisers backed expanded use of Merck’s ENFLONSIA to protect high-risk children from RSV through a second season, and belzutifan plus lenvatinib for advanced kidney cancer after prior immunotherapy. Both recommendations cover Liechtenstein, with European Commission decisions pending.

Pancreatic Cancer: The European Commission has approved RASONQUE (daraxonrasib) for adults with metastatic pancreatic cancer after at least one prior systemic treatment. Access will depend on country-specific pricing and reimbursement. Lung Cancer: EU medicines advisers recommend Zybrivo (sintilimab) with chemotherapy as a first-line option for advanced non-squamous lung cancer; the Commission must still decide. RSV Protection: European advisers back extending Merck’s ENFLONSIA to high-risk children under two through a second RSV season. Liechtenstein is among the countries covered by the pending Commission decision. Short Bowel Syndrome: The EU has approved Zeydovio (glepaglutide), a twice-weekly treatment for adults with short bowel syndrome and the first major European treatment advance for the condition in more than a decade. Kidney Cancer: Advisers also recommend belzutifan with lenvatinib for advanced kidney cancer after prior PD-1 or PD-L1 treatment; EU approval is pending.

Cancer Care: The European Medicines Agency’s medicines committee recommended Zybrivo with chemotherapy as a first-line option for adults with advanced non-squamous lung cancer; European Commission approval is still pending. The committee also backed belzutifan plus lenvatinib for some adults with advanced kidney cancer after prior treatment, with a final decision expected within two months. Rare Conditions: The European Commission approved Zeydovio for adults with short bowel syndrome, marking the first major treatment advance for the condition in Europe in more than a decade. Child Health: EU advisers recommended expanding Merck’s RSV prevention treatment to cover high-risk children through a second season. A final decision is expected within two months and would include Liechtenstein.

Cancer Treatment: European regulators recommended belzutifan plus lenvatinib for some adults with advanced kidney cancer after prior immunotherapy. The European Commission’s decision will also cover Liechtenstein and is expected within two months. RSV Prevention: EU advisers backed expanding Merck’s ENFLONSIA to protect high-risk children through a second RSV season; a final decision covering Liechtenstein is expected within two months. Short Bowel Syndrome: The European Commission approved Zealand Pharma’s Zeydovio for adults, offering a new treatment option after more than a decade without a major advance. Public Health: The ECDC is preparing Epi+, a digital platform to help countries detect and assess emerging health threats, with rollout planned next year.

RSV Prevention: EU regulators have backed expanding Merck’s ENFLONSIA to protect high-risk children under two through a second RSV season. The European Commission’s decision, covering Liechtenstein, is expected within two months. Cancer Treatment: The EMA has recommended belzutifan plus lenvatinib for adults with advanced kidney cancer after prior immunotherapy; the European Commission will decide on approval, including for Liechtenstein, in the coming months. Short Bowel Syndrome: The European Commission has approved Zealand Pharma’s Zeydovio for adults with the condition, introducing a new twice-weekly treatment option in Europe. Public Health Surveillance: The ECDC is preparing a multilingual platform to help countries detect and assess emerging health threats, with rollout planned next year.

RSV Prevention: European medicines advisers backed expanding Merck’s ENFLONSIA to protect high-risk children under two through a second RSV season. The European Commission’s decision, expected within two months, would cover Liechtenstein and other European countries. Short Bowel Syndrome: The European Commission approved Zealand Pharma’s Zeydovio for adults, marking the first major European treatment advance for the condition in more than a decade. Kidney Cancer: EU advisers recommended belzutifan plus lenvatinib for advanced clear-cell kidney cancer after prior immunotherapy; a final decision is expected within two months and would apply to Liechtenstein. Public Health Preparedness: The ECDC is preparing a multilingual surveillance platform for rollout next year, designed to help countries identify and assess emerging health threats and coordinate responses.

New Treatment: The European Commission has approved Zealand Pharma’s Zeydovio for adults with short bowel syndrome, the first major European treatment advance for the condition in more than a decade. RSV Protection: EU medicines advisers support extending Merck’s ENFLONSIA protection to high-risk children through a second RSV season. The European Commission is expected to decide within two months; the proposed coverage includes Liechtenstein. Kidney Cancer: Advisers also recommend belzutifan plus lenvatinib for advanced clear-cell kidney cancer after immunotherapy. The combination improved progression-free survival in a trial, though overall survival did not reach statistical significance; a final decision is expected within two months and would cover Liechtenstein. Emerging Infection: France has reported the first known human Shamonda virus infection. The patient, an older man with serious underlying illness, died; investigators are assessing the virus’s role. Health officials say one case does not establish a wider public threat.

Short Bowel Syndrome: The European Commission approved Zealand Pharma’s Zeydovio, a twice-weekly treatment for adults with short bowel syndrome. The company says it is the first major treatment advance for the condition in Europe in more than a decade. Kidney Cancer: The EU medicines committee recommended belzutifan with lenvatinib for advanced clear-cell kidney cancer after prior immunotherapy. The European Commission will decide whether to authorize the combination in the EU, Liechtenstein, Iceland and Norway. Public Health Preparedness: ECDC is training experts ahead of the planned rollout of Epi+, a platform to help countries track emerging health threats and coordinate responses. Emerging Infection: Authorities are investigating the first reported human Shamonda virus infection, found in France in an immunocompromised older man who died after severe encephalitis. Officials say one case does not establish a wider risk, and how the infection was acquired remains under investigation.

European Health Preparedness: ECDC is training experts ahead of Epi+, a surveillance platform planned for rollout in nine countries next year to help spot and assess emerging health threats. Liechtenstein’s participation was not specified. Shamonda Virus Watch: France is investigating the first confirmed human infection, in an older man with serious underlying illness who died after developing encephalitis. Officials say one case is not enough to gauge the risk to the wider public; infection may have come from an infected midge.

Public Health Preparedness: The ECDC is training epidemiologists ahead of next year’s planned Epi+ surveillance rollout in nine countries. The platform is designed to help public health agencies share information and assess emerging threats; the agency says it will complement its existing EpiPulse system. Emerging Infection: Health officials are investigating the first known human infection with Shamonda virus, detected in an older, immunocompromised man in eastern France who died after developing severe encephalitis. The ECDC says it is not yet clear whether the virus caused or contributed to his death. A single case does not indicate a wider threat, and officials are still examining how the infection occurred.

European Preparedness: The ECDC is training national experts ahead of next year’s Epi+ rollout in nine countries. The platform is designed to help public health agencies spot and assess emerging threats and coordinate responses across borders. Emerging Infection: France is investigating the first reported human case of Shamonda virus, in an immunocompromised older man who died after developing severe encephalitis. The virus’s role in his illness is still being examined; experts caution that one case is not enough to judge the risk to the wider public. An infected midge is considered the likeliest source.

Emerging Infection: WHO is investigating the first confirmed human Shamonda virus case, in an immunocompromised older man in eastern France who developed severe encephalitis and died. Officials say only one human infection has been reported, so the risks to people remain unclear; an infected midge is considered the likeliest source. Longevity Trends: A Zurich investment conference put “healthspans” among the themes drawing investor interest, alongside AI and digital assets, reflecting growing attention to health and ageing as market forces.

Emerging Infection: WHO and European health officials are investigating the first known human Shamonda virus infection, in an immunocompromised older man in France who died after developing encephalitis. Officials say one case is not enough to assess wider risk; transmission from an infected midge is considered most likely. Cancer Treatment: Anktiva, used with BCG for certain bladder cancers, has been given to its first patients in Germany and Austria. Its conditional European approval also covers Liechtenstein, though the report does not say when it will be available locally.

Cancer Care: The first European patients have received ImmunityBio’s Anktiva with BCG for certain hard-to-treat bladder cancers, in Germany and Austria. Its conditional EU approval also covers Liechtenstein. Emerging Infection: WHO is investigating the first confirmed human Shamonda virus case, in an immunocompromised older man in eastern France who died after developing severe encephalitis. Officials say one case does not establish a wider public-health risk; a midge bite is considered the likeliest route of infection.

Emerging Infection: WHO is investigating the first confirmed human case of Shamonda virus, in an older, immunocompromised man in France who died after developing severe encephalitis. Officials say one case does not establish a wider public-health threat, and how he was infected remains under investigation. Insurance: Genki has expanded its international health plan, allowing cover from one month and adding preventive and dental care. The policy is underwritten by Liechtenstein-based Squarelife Insurance AG. Cancer Care: ImmunityBio says the first European patients have received Anktiva with BCG for certain bladder cancers. The European Commission’s conditional approval also covers Liechtenstein. Infectious Disease Treatment: Basilea received a $37.5 million milestone payment after strong European sales of antifungal Cresemba, which is approved in Liechtenstein and other European markets for invasive fungal infections.

Emerging Infection: France is investigating the first known human case of Shamonda virus after an immunocompromised older man died with severe encephalitis. The WHO says the risk to the wider public is unclear; only one human infection has been reported. Health Insurance: Liechtenstein-based Squarelife underwrites Genki Native, an international health plan now available for periods from one month, with expanded preventive and dental cover. Cancer Care: Europe’s first patients have received ImmunityBio’s Anktiva with BCG for certain bladder cancers in Germany and Austria. The treatment’s conditional EU approval also covers Liechtenstein. Antifungal Medicines: Strong European sales of Cresemba triggered a $37.5 million payment to Basilea. The antifungal is approved in Liechtenstein for intravenous use in patients aged one and older.

Emerging Infection: Health officials are investigating the first confirmed human Shamonda virus infection, in an immunocompromised older man in France who died after developing encephalitis. The source is unclear, and experts say one case does not show a wider risk to the public. Medicine Safety: The European Medicines Agency is reviewing Deanxit after reports of movement disorders and memory problems, some of which reportedly continued after treatment stopped. Cancer Care: The first European patients have received ImmunityBio’s bladder cancer treatment Anktiva with BCG in Germany and Austria; its conditional European approval also covers Liechtenstein. Health Cover: Liechtenstein-based insurer Squarelife is backing Genki Native’s expanded international health plan, which now offers cover from one month and adds preventive and dental care.

Emerging Infection: Health officials are investigating the first known human Shamonda virus infection, in an immunocompromised older man in France who died after developing encephalitis. The cause and source of infection remain unclear; a single case does not establish a wider public-health risk. Medicine Review: The European Medicines Agency is reviewing depression and anxiety drug Deanxit after reports of movement disorders and memory or thinking problems, sometimes persisting after treatment ends. Liechtenstein Insurance: Genki has shortened the minimum term for its worldwide health cover to one month and expanded preventive and dental benefits. The policy is underwritten by Liechtenstein-based Squarelife Insurance. Cancer Care: First European patients have received bladder-cancer treatment Anktiva in Germany and Austria. Its conditional European approval also covers Liechtenstein.

Shamonda Virus: Health authorities are investigating the first recorded human infection, in an immunocompromised older man in France who died after developing encephalitis. It is not yet clear whether the virus contributed to his death or how he became infected; experts caution that one case does not establish a wider risk. Cancer Care: Anktiva, a bladder-cancer treatment, has been given to its first patients in Europe, in Germany and Austria. Its conditional EU approval also covers Liechtenstein. Medicine Safety: The European Medicines Agency is reviewing Deanxit, used for depression and anxiety, after reports of movement disorders and problems with memory and thinking, sometimes persisting after treatment stopped. Health Cover: Genki has expanded its international health insurance, underwritten by Liechtenstein-based Squarelife, with cover options from one month and added preventive and dental care.

Emerging Infection: The WHO is investigating the first recorded human Shamonda virus case, after an older man in eastern France died from severe encephalitis. Infection is thought most likely to have come from an infected midge; human health risks remain unclear. Medicine Safety: The European Medicines Agency is reviewing Deanxit, used for depression and anxiety, after reports of serious movement, memory and thinking problems, some persisting after treatment stopped. Cancer Care: Anktiva, conditionally approved across the EU and in Liechtenstein, has been given to its first European patients in Germany and Austria for a form of bladder cancer that has not responded to BCG treatment. Health Cover: Genki has expanded its international health insurance, underwritten by Liechtenstein-based Squarelife, with cover from one month and expanded preventive and dental benefits.

Sign up for:

Health Monitor Liechtenstein

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Health Monitor Liechtenstein

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.